In the comparison between the two groups, a statistically significantly higher improvement was found in the P20 group compared to the P12 group for the FIQ subscales of stiffness (p=0.001) and the number of days during which the patient felt “good” (p=0.007).Conclusion: An intensive program of daily treatments and activity seems to be more effective in reducing fibromyalgia-associated stiffness and improving the number of days during which patients feel good than a less intensive program.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Objectives: This study aims to evaluate the effectiveness of two multidisciplinary fibromyalgia programs with different intensities.Materials and methods: In this retrospective real-world comparison of patient data, pre- and post-program datasets of Short Form 36 (SF36) and Fibromyalgia Impact Questionnaire (FIQ) were obtained from a total of 210 female patients in two fibromyalgia multidisciplinary day hospital programs including one intensive program with daily treatments summing up to 20 treatment days during four weeks (P20, n=70) versus a less intensive program with 12 treatment days during four weeks (P12, n=140).Results: Multiple subscales of SF36 and FIQ were improved in the pre-post comparison in both groups.
📊
Temel Bulgular & Veri:Objectives: This study aims to evaluate the effectiveness of two multidisciplinary fibromyalgia programs with different intensities.Materials and methods: In this retrospective real-world comparison of patient data, pre- and post-program datasets of Short Form 36 (SF36) and Fibromyalgia Impact Questionnaire (FIQ) were obtained from a total of 210 female patients in two fibromyalgia multidisciplinary day hospital programs including one intensive program with daily treatments summing up to 20 treatment days during four weeks (P20, n=70) versus a less intensive program with 12 treatment days during four weeks (P12, n=140).Results: Multiple subscales of SF36 and FIQ were improved in the pre-post comparison in both groups.
💡
Sonuç & Katkı:In the comparison between the two groups, a statistically significantly higher improvement was found in the P20 group compared to the P12 group for the FIQ subscales of stiffness (p=0.001) and the number of days during which the patient felt “good” (p=0.007).Conclusion: An intensive program of daily treatments and activity seems to be more effective in reducing fibromyalgia-associated stiffness and improving the number of days during which patients feel good than a less intensive program.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Objectives: This study aims to evaluate the effectiveness of two multidisciplinary fibromyalgia programs with different intensities.Materials and methods: In this retrospective real-world comparison of patient data, pre- and post-program datasets of Short Form 36 (SF36) and Fibromyalgia Impact Questionnaire (FIQ) were obtained from a total of 210 female patients in two fibromyalgia multidisciplinary day hospital programs including one intensive program with daily treatments summing up to 20 treatment days during four weeks (P20, n=70) versus a less intensive program with 12 treatment days during four weeks (P12, n=140).Results: Multiple subscales of SF36 and FIQ were improved in the pre-post comparison in both groups. In the comparison between the two groups, a statistically significantly higher improvement was found in the P20 group compared to the P12 group for the FIQ subscales of stiffness (p=0.001) and the number of days during which the patient felt “good” (p=0.007).Conclusion: An intensive program of daily treatments and activity seems to be more effective in reducing fibromyalgia-associated stiffness and improving the number of days during which patients feel good than a less intensive program.
🔖
Bu Makaleye Atıf Yap
KRAMER, S., DEUSCHLE, L., KOHLS, N., CHER, M. O., WINKELMANN, A. (2020). The Importance of Daily Activity for Reducing Fibromyalgia Symptoms: A Retrospective “Real World” Data Comparison of two Multimodal Treatment Programs. art, Cilt: 35 - Sayı: 4, 575–583. https://ajindex.com/articles/351659
Lacasse A, Bourgault P, Choinière M. Fibromyalgiarelated costs and loss of productivity: a substantial societal burden. BMC Musculoskelet Disord 2016;17:168
Thompson JM, Luedtke CA, Oh TH, Shah ND, Long KH, King S, et al. Direct medical costs in patients with fibromyalgia: Cost of illness and impact of a brief multidisciplinary treatment program. Am J Phys Med Rehabil 2011;90:40-6
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
Bernardy K, Klose P, Welsch P, Häuser W. Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome - A systematic review and meta-analysis of randomized controlled trials. Eur J Pain 2018;22:242-60
Welsch P, Bernardy K, Derry S, Moore RA, Häuser W. Mirtazapine for fibromyalgia in adults. Cochrane Database Syst Rev 2018;8:CD012708
Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev 2018;2:CD010292
Aman MM, Jason Yong R, Kaye AD, Urman RD. Evidence-Based Non-Pharmacological Therapies for Fibromyalgia. Curr Pain Headache Rep 2018;22:33
Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev 2018;2:CD010585
Üçeyler N, Sommer C, Walitt B, Häuser W. WITHDRAWN: Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 2017;10:CD010782
Johnson MI, Claydon LS, Herbison GP, Jones G, Paley CA. Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults. Cochrane Database Syst Rev 2017;10:CD012172
Baranowsky J, Klose P, Musial F, Häuser W, Dobos G, Langhorst J. Qualitative systemic review of randomized controlled trials on complementary and alternative medicine treatments in fibromyalgia. Rheumatol Int 2009;30:1-21
Langhorst J, Klose P, Dobos GJ, Bernardy K, Häuser W. Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2013;33:193-207
Sommer C, Alten R, Bär KJ, Bernateck M, Brückle W, Friedel E, et al. Drug therapy of fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles. Schmerz 2017;31:274-84